2025-08-21 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, presented in English with key figures, analysis, and a summary.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

**1. Performance Relative to S&P 500 (VOO)**

*   **Ticker:** RXRX
*   **Company Description:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company using AI to discover, develop, and commercialize novel medicines.
*   **RXRX Cumulative Return:** -46.74%
*   **VOO Cumulative Return:** 37.28%
*   **Relative Divergence:**
    *   Maximum: 35.8
    *   Minimum: -88.1
    *   Current: -85.4
    *   Relative Position: 2.2

**Analysis of Provided Table**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
| ---------- | ------- | ----- | ------ | ---- | ------ |
| 2021-2023  | 8.0%    | 73.6% | -2.0%  | -0.1 | 4.3    |
| 2022-2024  | -11.0%   | 73.6% | -41.0% | 0.0  | 2.9    |
| 2023-2025  | 2.0%    | 73.6% | -41.0% | 0.0  | 2.1    |

**Analysis:**
*   **Negative Alpha:** Recursion has consistently underperformed the market benchmark (negative alpha) over the observed periods. The negative alpha is quite large (-41.0%) in the 2022-2024 and 2023-2025 periods.
*   **Low/Negative Beta:** The beta values are very low (close to 0 or negative), indicating that RXRX's price movements are not strongly correlated with the overall market.
*   **High MDD:** The Maximum Drawdown (MDD) is consistently high (73.6%), suggesting significant volatility and potential for large losses.
*   **Capitalization (Cap):** The company's market capitalization has decreased from $4.3B to $2.1B over the observed periods.

**2. Recent Stock Price Movement**

*   **Current Price:** \$4.77
*   **Previous Close:** \$5.09
*   **Change:** -6.29% (Significant drop)
*   **5-Day Moving Average:** \$5.358
*   **20-Day Moving Average:** \$5.661
*   **60-Day Moving Average:** \$5.341

**Analysis:** The current price is below all moving averages, indicating a downward trend. The recent -6.29% change suggests significant selling pressure.

**3. Market Risk Indicator, RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3316 (Low Risk)
*   **RSI:** 26.40 (Oversold)
*   **PPO:** -1.7577
*   **Hybrid Signal:** cash_70%_Sell 70.0% of holdings (3484 shares - Caution - MRI:0.34) (Cash Ratio: 70% on 2025-07-31)
*   **Recent (20-day) Relative Divergence Change:** -1.4 (Negative - Short-term decline)
*   **Expected Return:** -1178.0% (Long-term, relative to S&P 500)

**Analysis:** The RSI indicates that the stock is oversold, which could suggest a potential for a short-term bounce. However, the significantly negative expected return indicates a very pessimistic outlook for long-term outperformance compared to the S&P 500. The Hybrid Signal recommends a high cash position (70%) and selling a significant portion of holdings, reflecting a cautious stance. The MRI indicates the market risk is low, but this may not be fully representative given the other negative indicators specific to RXRX.

**4. Recent News & Significant Events**

*   **2025-08-17:** Major business developments, regulatory changes, or market events.
*   **2025-08-19:** Analyst discussions on recent performance and outlook.
*   **2025-08-21:** Notable stock volatility.
*   **2025-08-18:** Market experts highlighting risks and opportunities.

**Analysis:**  The news suggests RXRX is experiencing volatility and is under scrutiny. Investors are advised to monitor company announcements and news.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
| ---------- | ----- | ---------- |
| 2025-08-05 | -0.41 | \$0.02B    |
| 2025-05-05 | -0.5  | \$0.01B    |
| 2024-11-06 | -0.34 | \$0.03B    |
| 2024-08-08 | -0.4  | \$0.01B    |
| 2025-08-05 | -0.4  | \$0.01B    |

**Analysis:** The company consistently reports negative EPS, indicating a lack of profitability. Revenue has fluctuated but generally remains low.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-06-30 | \$0.02B    | -5.54%        |
| 2025-03-31 | \$0.01B    | -47.31%       |
| 2024-12-31 | \$0.00B    | -183.62%      |
| 2024-09-30 | \$0.03B    | 53.69%        |
| 2024-06-30 | \$0.01B    | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-06-30 | \$0.92B    | -18.70%   |
| 2025-03-31 | \$0.93B    | -21.68%   |
| 2024-12-31 | \$1.03B    | -17.29%   |
| 2024-09-30 | \$0.52B    | -18.27%   |
| 2024-06-30 | \$0.58B    | -16.69%   |

**Analysis:** Revenue is inconsistent. Profit margins are generally negative, indicating the company is struggling to generate profits. While equity has been maintained above \$0.9B recently, Return on Equity (ROE) is consistently negative, reinforcing the lack of profitability.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) exhibits several concerning indicators:

*   **Underperformance:** Significantly underperforming the S&P 500, both in recent performance and long-term projections.
*   **Volatility:** High Maximum Drawdown indicates substantial price swings. Recent news confirms ongoing volatility.
*   **Lack of Profitability:** Consistent negative EPS, negative profit margins, and negative ROE highlight significant challenges in generating profits.
*   **Downward Trend:** The stock price is below key moving averages, indicating a downward trend, exacerbated by a recent large price drop.
*   **Cautious Signals:** Hybrid Signal suggests reducing exposure and increasing cash position.

**Conclusion:**  Based on this data, RXRX appears to be a high-risk investment. While the RSI suggests a potential for a short-term rebound, the negative long-term outlook, lack of profitability, and recent negative price action warrant extreme caution. Further research and careful monitoring of company announcements and news are crucial for any investor considering RXRX.
